31 results about "Solifenacin Succinate" patented technology

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a solifenacin succinate-containing orally disintegrating tablet and a preparation method thereof. The orally disintegrating tablet is clinically used for treating symptoms such as frequent micturition, urgent urination and urinary incontinence caused by the overactive bladder.

The invention relates to a preparation technology of solifenacin succinate. According to the preparation technology, (S)-1-phenyl-1, 2, 3, 4-tetrahydroisoquinoline carbamyl chloride (II) and (R)-3-quinuclidine alcohol metal salt (III) are reacted to generate solifenacin alkali, and then the solifenacin alkali is prepared into solifenacin succinate. With the adoption of the preparation technology provided by the invention, nucleophilic species which lead to a reverse reaction can be avoided during condensation process, namely, the reverse reaction cannot be generated in the preparation technology, therefore, a transformation rate of the solifenacin succinate is improved, a reaction is greatly promoted, a reaction process is quickly carried out under a mild condition, and the preparation technology is suitable for large-scale production.

The invention relates to a pharmaceutical composition containing solifenacin succinate. The pharmaceutical composition is characterized by simultaneously containing direct compression lactose, sodium carboxymethyl starch, a binder and a lubricating agent. The invention also discloses a preparation method, namely a direct powder compression method of the pharmaceutical composition. The pharmaceutical composition and the preparation method thereof are not influenced by water in the preparation process, the pharmaceutical composition is low in impurity content and better in drug dissolubility, and the preparation method is more suitable for industrial production.

There is provided an agent comprising solifenacin succinate in an amount of 5 mg to 10 mg or solifenacin or a pharmaceutically acceptable salt thereof in an amount equimolar to 5 mg to 10 mg of solifenacin succinate for improvement of urinary urgency, pollakiuria and urinary incontinence due to neurogenic bladder caused by neurodegenerative diseases such as cerebrovascular disease or cerebral infarction, brain or spinal cord injury due to trauma, multiple sclerosis, Parkinson's disease, congenital malformation of the nerve system, peripheral neuropathy, and various spine lesions, that is, spinal cord compression and injury due to fracture, cervical and lumbar spondylosis, spondylosis deformans, spondylolisthesis, spinal stenosis, vertebral disk hernia and the like.

Provided is a package that exhibits satisfactory moldability as well as moisture adsorption and gas adsorption properties.

A package P includes a container sheet 6 in which a concave receptacle unit 5 that accommodates a solid preparation 8 containing solifenacin succinate or 1-{[α-isobutanoyloxyethoxy]carbonyl}aminomethyl}-1-cyclohexaneacetic acid is formed, and an airtight cover material sheet 7 for sealing the solid preparation 8. The container sheet 6 is formed by a package film F1 in which an adsorption layer 1, at least one or more substrate layers 2 formed by resins, an aluminum foil 3, and a barrier layer 4. The adsorption layer 1 is laminated with the substrate layer 2 while also being disposed on the side where the solid preparation 8 is accommodated, and contains at least zeolite.

The invention relates to an analysis method for determining stereoisomers and intermediates in solifenacin succinate by adopting high-performance liquid chromatography. The analysis method is characterized in that high-performance liquid chromatography (HPLC) is adopted, and isocratic elution is carried out on an amylose-tris(3,5-dimethylphenyl carbamate) bonded silica gel chiral HPLC column; a mobile phase is n-hexane-absolute ethyl alcohol-isopropyl alcohol-diethylamine solution (65:15:20:0.1) (volume ratio); and the mobile phase is adopted to dissolve a sample. The method can be used for simultaneously determining enantiomers and a diastereoisomer of the solifenacin succinate and intermediates as mutual enantiomers, thus providing a more reliable guarantee for the research on new synthesis process routes for the solifenacin succinate and quality control.

The invention provides a stable pharmaceutical composition and its preparation method. The pharmaceutical composition contains solifenacin succinate and hydroxypropyl methylcellulose, wherein viscosity of hydroxypropyl methylcellulose is 1-4mPa.s.

The invention relates to a preparation method for an impurity of Solifenacin succinate, i.e., [2-(2-benzoyl-phenyl)-ethyl]-1-aza-bicyclo[2.2.2]octyl-3-carbamate. The impurity is prepared through carrying out oxidation ring-opening on Solifenacin succinate and then carrying out separation and purification. According to the preparation method, through preparing the impurity of Solifenacin succinate, a reference substance for qualitative and quantitative analysis on Solifenacin succinate is provided, the quality of Solifenacin succinate is effectively controlled, and thus the safety of clinical medication is guaranteed.

The invention relates to a method for preparing a solifenacin succinate ((3R)-1-azabicyclo [2.2.2] octane-3-yl (1S)-1-phenyl-3,4-dihydroisoquinoline-2-(1H)-carboxylate succinate). The method comprises the following steps: 1) preparing a compound (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline carboxylic acid ethyl ester of formula III from a compound (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline, serving as a raw material, of formula IV; 2) synthesizing a compound (3R)-1-azabicyclo [2.2.2] octane-3-yl (1S)-1-phenyl-3,4-dihydroisoquinoline-2-(1H)-carboxylate of formula II in an ionic liquid by using the compound (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline carboxylic acid ethyl ester of formula III; and 3) salifying the compound (3R)-1-azabicyclo [2.2.2] octane-3-yl (1S)-1-phenyl-3,4-dihydroisoquinoline-2-(1H)-carboxylate of formula II in an organic solvent to obtain the compound solifenacin succinate ((3R)-1-azabicyclo [2.2.2] octane-3-yl (1S)-1-phenyl-3,4-dihydroisoquinoline-2-(1H)-carboxylate succinate) of formula I. The preparation method has the advantages that the process is simple, the method is suitable for industrialized production, the yield of the product is high and the purity of the product is high.

The invention provides an analysis method for detecting R-3-quinuclidinol in solifenacin succinate by high performance liquid chromatography. The method is characterized in that high performance liquid chromatography is adopted, and a chromatographic column adopting aminopropyl bonded silica gel as a filling agent is employed; an ultraviolet detector which has the detection wavelength of 210 nm is used; the mobile phase is an n-hexane-ethanol-methanol-diethylamine (600:300:100:1) solution; a sample is dissolved by the mobile phase and has the concentration of 20 mg/ml, and quantitative analysis is made according to peak area by the external standard method. The method has the advantages of being good in selectivity, high in sensitivity and accuracy, excellent in repeatability, and simple, convenient and quick, and provides a guarantee for accurate detection of R-3-quinuclidinol in solifenacin succinate.

The invention discloses a synthesis method of solifenacin succinate. The synthesis method comprises the following processing steps: (1) respectively dissolving (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline, organic alkali and triphosgene into a proper amount of high-boiling-point solvent, dropwise adding the (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline and a solution of the organic alkali to the solution of the triphosgene, so as to obtain an intermediate (S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-formyl chloride, and finally adding a proper amount of organic alkali and high-boiling-point solvent, adding (R)-3-quinuclidinol, heating to 100-200 DEG C and carrying out temperature control reaction, so as to prepare solifenacin; and (2) dissolving the solifenacin into a mixed solvent of ethyl acetate and ethyl alcohol, adding new seed crystal of the solifenacin succinate, stirring and crystallizing, so as to prepare the solifenacin succinate. The synthesis method of the solifenacin succinate has the advantages that two-step condensation reaction is carried out by virtue of a one-pot operation in the synthesis method, so that the troublesome azeotropic separation operation reported in the literature is avoided; and homogeneous catalysis is carried out by selecting soluble organic alkali, so that the reaction efficiency is improved.

The invention discloses a solifenacin succinate raw medicine synthesis process. 2-phenylethylamine and 3-quinuclidinone hydrochloride are respectively used as starting raw materials for synthesizing afragment A and a fragment B; then, condensation reaction occurs to generate solifenacin; through salt formation, the solifenacin succinate is obtained. The process is characterized in that straight-chain paraffin and water are used as reaction solvents; alkali metal hydroxides or carbonate and bicarbonates of the alkali metal hydroxides are used as acid-binding agents; phenylethylamine and benzoyl chloride take acylation reaction to generate midbodies 1 of solid precipitation fragments A insoluble in reaction solvents; in the post treatment process, filtering is directly performed; isomers ofthe fragment A are subjected to catalytic racemization through alkali metal hydroxides by using dimethylsulfoxide as a solvent, so that the byproduct isomers can be recovered and utilized; in the second-step reaction post treatment of the fragment B, a conventional pressure reduced distillation method is used for obtaining high-purity and high-yield 3-acetoxyquinine acetate. The invention provides a novel synthesis process with the advantages of high yield and economic and environment-friendly effects, and is suitable for industrial mass production.

The present invention relates to a process for the preparation of Solifenacin succinate by condensing a compound of formula (IVb) with (RS)-3-quinuclidinol, wherein, R represents methyl, ethyl, isopropyl; to produce a diastereomeric mixture of (1S)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylic acid (3RS)-1-azabicyclo[2.2.2]oct-3-yl ester, which is treated with succinic acid in a solvent or mixture of solvents to produce optically pure Solifenacin succinate, Formula (X).

The present invention relates to a pharmaceutical multi layer tablet comprising a controlled release part with mirabegron and an immediate release part wherein the immediate release formulation comprises: solifenacin succinate and a water insoluble diluent in an amount of 50 to 99% w/w relative to the total weight of the immediate release part of the tablet. The invention further relates to the use of said composition as a medicament, particularly in the treatment of urinary incontinence.

The invention discloses a synthesis process of solifenacin succinate, and relates to the technical field of medicines. The preparation method comprises the following steps: step 1, reacting (R)-quinuclidin-3-ol (B) with a reaction substance to generate (R)-quinuclidin-3-yl carbonochloridate (C); step 2, enabling (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline (A) to react with (R)-quinuclidin-3-yl carbonochloridate (C) to generate solifenacin (D); and step 3, using the solifenacin (D) to prepare the solifenacin succinate. After the technical scheme is adopted, the method has the beneficial effects that in the synthesis process, the problem of low conversion rate caused by direct ester exchange reaction is avoided, meanwhile, the probability of reversible reaction caused by nucleophilic intermediate products generated in the condensation process is also reduced, and the reaction is greatly promoted, so that the yield of solifenacin succinate is increased, the reaction conditions are mild, the operation is simple, the operation procedures are reduced, and the method is suitable for large-scale production.

The invention provides a solifenacin succinate tablet and a preparation method thereof. The solifenacin succinate tablet comprises the following components: solifenacin succinate, trehalose, a disintegrating agent and a hydrophobic adhesive. The solifenacin succinate tablet disclosed by the invention is relatively good in uniformity and relatively high in medication safety.

The invention discloses a preparation process of a solifenacin succinate tablet composition. The preparation process comprises the following specific preparation steps: step 1, pretreatment: sieving solifenacin succinate and lactose by a 40-mesh sieve for later use; step 2, weighing: according to a batch prescription, re-checking and weighing the solifenacin succinate, the lactose, corn starch andhydroxypropyl methylcellulose by two persons; step 3, solution preparation: preparing 460g of 8% hydroxypropyl methylcellulose solution from the weighed hydroxypropyl methylcellulose; and step 4, preheating and primary mixing: according to the batch prescription, after the feeding amount is checked by two persons, sequentially adding the lactose, the solifenacin succinate (more different in process, directly adding or adding together with an adhesive) and the corn starch into a multifunctional fluidized bed in sequence, and preheating and mixing for 12min. The preparation effect is more outstanding by utilizing the cooperation of multiple steps, and the process is simple compared with the existing preparation technology, large-batch production can be carried out, and the production cost is greatly reduced.